PT - JOURNAL ARTICLE AU - Das, Debodipta AU - Wang, Xiaojing AU - Chiu, Yu-Chiao AU - Bouamar, Hakim AU - Sharkey, Francis E. AU - Lopera, Jorge E. AU - Lai, Zhao AU - Weintraub, Susan T. AU - Han, Xianlin AU - Zou, Yi AU - Chen, Hung-I H. AU - Zeballos Torrez, Carla R. AU - Gu, Xiang AU - Cserhati, Matyas AU - Michalek, Joel E. AU - Halff, Glenn A. AU - Chen, Yidong AU - Zheng, Siyuan AU - Cigarroa, Francisco G. AU - Sun, Lu-Zhe TI - Integrative multi-omics characterization of hepatocellular carcinoma in Hispanic patients AID - 10.1101/2024.04.27.24306447 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.27.24306447 4099 - http://medrxiv.org/content/early/2024/04/30/2024.04.27.24306447.short 4100 - http://medrxiv.org/content/early/2024/04/30/2024.04.27.24306447.full AB - Background The incidence and mortality rates of hepatocellular carcinoma (HCC) among Hispanics in the United States are much higher than those of non-Hispanic whites. We conducted comprehensive multi-omics analyses to understand molecular alterations in HCC among Hispanic patients.Methods Paired tumor and adjacent non-tumor samples were collected from 31 Hispanic HCC in South Texas (STX-Hispanic) for genomic, transcriptomic, proteomic, and metabolomic profiling. Additionally, serum lipids were profiled in 40 Hispanic and non-Hispanic patients with or without clinically diagnosed HCC.Results Exome sequencing revealed high mutation frequencies of AXIN2 and CTNNB1 in STX Hispanic HCCs, suggesting a predominant activation of the Wnt/β-catenin pathway. The TERT promoter mutation frequency was also remarkably high in the Hispanic cohort. Cell cycles and liver functions were identified as positively- and negatively-enriched, respectively, with gene set enrichment analysis. Gene sets representing specific liver metabolic pathways were associated with dysregulation of corresponding metabolites. Negative enrichment of liver adipogenesis and lipid metabolism corroborated with a significant reduction in most lipids in the serum samples of HCC patients. Two HCC subtypes from our Hispanic cohort were identified and validated with the TCGA liver cancer cohort. The subtype with better overall survival showed higher activity of immune and angiogenesis signatures, and lower activity of liver function-related gene signatures. It also had higher levels of immune checkpoint and immune exhaustion markers.Conclusions Our study revealed some specific molecular features of Hispanic HCC and potential biomarkers for therapeutic management of HCC and provides a unique resource for studying Hispanic HCC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the Clayton Foundation for Research to FGC and L-Z S, by NIH cancer center support grant P30 CA054174 to the Shared Resources of Mays Cancer Center's Next Generation Sequencing and Mass Spectrometry. Next Generation Sequencing Shared Resource is also supported by NIH Shared Instrument grant S10 OD030311 and CPRIT Core Facility Award (RP220662), and R50 CA265339-01A1 to Z. Lai. Mass spectrometry analyses were also supported in part by the University of Texas System Proteomics Core Network for purchase of the Orbitrap Fusion Lumos mass spectrometer, with expert technical assistance of Sammy Pardo and Dana Molleur. The Functional Lipidomics Core at the University of Texas Health Science Center at San Antonio was partially supported by P30 AG013319 and P30 AG044271. CRZ was supported by NIH T32CA148724 and F32CA228435 training grants. The TCGA-LIHC datasets used for the analyses described in this manuscript were obtained from dbGap at https://www.ncbi.nlm.nih.gov/gap/ through dbGap accession phs000178.v10.p8 under the South Texas Liver Cancer Study (project ID: 13485).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the University of Texas Health Science Center at San Antonio has approved the study. We have already added the statement "The study was approved by UT Health San Antonio Institutional Review Board" under the Methods section of our manuscript.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes